SE9802973D0 - Immediate release tablet - Google Patents

Immediate release tablet

Info

Publication number
SE9802973D0
SE9802973D0 SE9802973A SE9802973A SE9802973D0 SE 9802973 D0 SE9802973 D0 SE 9802973D0 SE 9802973 A SE9802973 A SE 9802973A SE 9802973 A SE9802973 A SE 9802973A SE 9802973 D0 SE9802973 D0 SE 9802973D0
Authority
SE
Sweden
Prior art keywords
immediate release
release tablet
formulation
fillers
filler
Prior art date
Application number
SE9802973A
Other languages
English (en)
Swedish (sv)
Inventor
Sigbrit Forsman
Christer Karlsson
Magnus Karlsson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9802973A priority Critical patent/SE9802973D0/xx
Publication of SE9802973D0 publication Critical patent/SE9802973D0/xx
Priority to TW088114460A priority patent/TW561056B/zh
Priority to NZ539749A priority patent/NZ539749A/en
Priority to NZ509943A priority patent/NZ509943A/en
Priority to TR2001/00666T priority patent/TR200100666T2/xx
Priority to RU2001104423/15A priority patent/RU2252751C2/ru
Priority to CA002341397A priority patent/CA2341397C/fr
Priority to HU0103886A priority patent/HU227278B1/hu
Priority to CNB998103365A priority patent/CN1158070C/zh
Priority to SK281-2001A priority patent/SK285507B6/sk
Priority to EP99946527A priority patent/EP1109537B1/fr
Priority to IL14143999A priority patent/IL141439A0/xx
Priority to CNA2006100996728A priority patent/CN1951371A/zh
Priority to PCT/SE1999/001471 priority patent/WO2000013671A1/fr
Priority to KR1020067017052A priority patent/KR20060097071A/ko
Priority to EEP200100134A priority patent/EE200100134A/xx
Priority to US09/424,740 priority patent/US6521253B1/en
Priority to DK99946527T priority patent/DK1109537T3/da
Priority to CZ20010774A priority patent/CZ300830B6/cs
Priority to SI9930748T priority patent/SI1109537T1/xx
Priority to IDW20010429A priority patent/ID29629A/id
Priority to ES99946527T priority patent/ES2234296T3/es
Priority to CNA200410038573XA priority patent/CN1544088A/zh
Priority to KR1020017002726A priority patent/KR100696350B1/ko
Priority to AU58924/99A priority patent/AU746129B2/en
Priority to EP04030515A priority patent/EP1527787A1/fr
Priority to PT99946527T priority patent/PT1109537E/pt
Priority to AT99946527T priority patent/ATE286385T1/de
Priority to UA2001021082A priority patent/UA75567C2/uk
Priority to JP2000568480A priority patent/JP4026678B2/ja
Priority to DE69923074T priority patent/DE69923074T2/de
Priority to BR9913400-4A priority patent/BR9913400A/pt
Priority to PL99346545A priority patent/PL195603B1/pl
Priority to TR2005/02188T priority patent/TR200502188T2/xx
Priority to MYPI99003778A priority patent/MY124359A/en
Priority to ARP990104423A priority patent/AR029313A1/es
Priority to SA99200683A priority patent/SA99200683B1/ar
Priority to IL141439A priority patent/IL141439A/en
Priority to IS5869A priority patent/IS5869A/is
Priority to ZA200101762A priority patent/ZA200101762B/xx
Priority to NO20011085A priority patent/NO20011085L/no
Priority to US10/347,968 priority patent/US6875446B2/en
Priority to RU2005100986/15A priority patent/RU2005100986A/ru
Priority to US11/095,933 priority patent/US20050208128A1/en
Priority to JP2006309957A priority patent/JP2007039472A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9802973A 1998-09-03 1998-09-03 Immediate release tablet SE9802973D0 (sv)

Priority Applications (45)

Application Number Priority Date Filing Date Title
SE9802973A SE9802973D0 (sv) 1998-09-03 1998-09-03 Immediate release tablet
TW088114460A TW561056B (en) 1998-09-03 1999-08-24 Oral immediate release formulation of the thrombin inhibitor
CNA200410038573XA CN1544088A (zh) 1998-09-03 1999-08-27 即时释放片剂
IDW20010429A ID29629A (id) 1998-09-03 1999-08-27 Tablet yang lapas-segera
KR1020017002726A KR100696350B1 (ko) 1998-09-03 1999-08-27 급속 방출 정제
TR2001/00666T TR200100666T2 (tr) 1998-09-03 1999-08-27 Hemen yayılan tablet.
NZ509943A NZ509943A (en) 1998-09-03 1999-08-27 Immediate release tablet for low molecular weight peptide based thrombin inhibitors
CA002341397A CA2341397C (fr) 1998-09-03 1999-08-27 Comprime a liberation immediate
HU0103886A HU227278B1 (en) 1998-09-03 1999-08-27 Immediate release tablet comprising a peptide-base trombin inhibitor process for their preparation and their use
CNB998103365A CN1158070C (zh) 1998-09-03 1999-08-27 即时释放片剂
SK281-2001A SK285507B6 (sk) 1998-09-03 1999-08-27 Orálny prípravok na okamžité uvoľňovanie v pevnejforme, spôsob jeho prípravy a jeho použitie
EP99946527A EP1109537B1 (fr) 1998-09-03 1999-08-27 Formulation pharmaceutique orale a liberation immediate comprenant des peptides inhibiteurs de thrombine et une combinaison de la cellulose microcristalline et le sel de sodium du glycolate d'amidon
IL14143999A IL141439A0 (en) 1998-09-03 1999-08-27 Immediate release tablet
CNA2006100996728A CN1951371A (zh) 1998-09-03 1999-08-27 即时释放片剂
PCT/SE1999/001471 WO2000013671A1 (fr) 1998-09-03 1999-08-27 Comprime a liberation immediate
KR1020067017052A KR20060097071A (ko) 1998-09-03 1999-08-27 급속 방출 정제
EEP200100134A EE200100134A (et) 1998-09-03 1999-08-27 Kiiresti vabastav tablett
US09/424,740 US6521253B1 (en) 1998-09-03 1999-08-27 Immediate release tablet
AU58924/99A AU746129B2 (en) 1998-09-03 1999-08-27 Immediate release tablet
CZ20010774A CZ300830B6 (cs) 1998-09-03 1999-08-27 Orální prostredek s bezprostredním uvolnováním v tuhé forme, pro profylaxi a/nebo lécení tromboembolie a zpusob jeho výroby
SI9930748T SI1109537T1 (en) 1998-09-03 1999-08-27 Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate
NZ539749A NZ539749A (en) 1998-09-03 1999-08-27 Immediate release tablets of thrombin inhibitors i.e. melagatran and inogatran comprsing strach and cellulose as fillers
ES99946527T ES2234296T3 (es) 1998-09-03 1999-08-27 Formulacion oral de liberacion inmediata que comprende inhibidores peptidicos de trombina y una combinacion de celulosa microcristalina y almidon-glicolato de sodio.
TR2005/02188T TR200502188T2 (tr) 1998-09-03 1999-08-27 Hemen yayılan tablet
RU2001104423/15A RU2252751C2 (ru) 1998-09-03 1999-08-27 Таблетка с немедленным высвобождением
DK99946527T DK1109537T3 (da) 1998-09-03 1999-08-27 Oral formulering med öjeblikkelig frigivelse omfattende peptid-thrombininhibitorer og en kombination af mikrokrystallinsk cellulose og natriumstivelsesglycolat
EP04030515A EP1527787A1 (fr) 1998-09-03 1999-08-27 Comprimés à libération immédiate
PT99946527T PT1109537E (pt) 1998-09-03 1999-08-27 Formulacao oral de libertacao imediata compreendendo inibidores peptidicos de trombina e uma combinacao de celulose microcristalina e glicolato de amido de sodio
AT99946527T ATE286385T1 (de) 1998-09-03 1999-08-27 Oral anzuwendendes rasch-freisetzendes arzneimittel enthaltend peptid-thrombinhemmer und eine mischung von mikrokristallinen zellulose und natrium stärke glycollaten
UA2001021082A UA75567C2 (en) 1998-09-03 1999-08-27 Oral formulation containing thrombin inhibitor, process for their manufacture and method for preventing and treating thrombembolism
JP2000568480A JP4026678B2 (ja) 1998-09-03 1999-08-27 速放性錠剤
DE69923074T DE69923074T2 (de) 1998-09-03 1999-08-27 Oral anzuwendendes rasch-freisetzendes arzneimittel enthaltend peptid-thrombinhemmer und eine mischung von mikrokristallinen zellulose und natrium stärke glycollaten
BR9913400-4A BR9913400A (pt) 1998-09-03 1999-08-27 Formulação oral de liberação imediata na forma sólida de um inibidor de trombina, uso de um inibidor de trombina baseado em peptìdeo de baixo peso molecular, processos para a profilaxia e/ou o tratamento de trombo-embolismo, e para a preparação de uma formulação oral de liberação imediata, e, uso de uma carga escolhida do grupo consistindo de um derivado de celulose, e um derivado de amido
PL99346545A PL195603B1 (pl) 1998-09-03 1999-08-27 Preparat doustny o natychmiastowym uwalnianiu, zastosowanie niskocząsteczkowego peptydowego inhibitora trombiny, sposób wytwarzania preparatu doustnego oraz zastosowanie mieszaniny celulozy mikrokrystalicznej i soli sodowej glikolanu skrobi
MYPI99003778A MY124359A (en) 1998-09-03 1999-09-01 Immediate release tablet
ARP990104423A AR029313A1 (es) 1998-09-03 1999-09-02 Formulacion oral de liberacion inmediata en forma solida. uso de un inhibidor de trombina peptidico de bajo peso molecular para la elaboracion de dicha formulacion. metodo para la profilaxis y/o tratamiento de la tromboembolia y proceso para la preparacion de dicha formulacion
SA99200683A SA99200683B1 (ar) 1998-09-03 1999-10-18 صيغ لإطلاق الفوري تعطي عن طريق الفم تشتمل على مثبطات ثرومبين ببتيدي peptide thrombin inhbitor وتوليفة من بلورات دقيقة من السليولوز microystalline cellulose وجليكولات صوديوم نشوية glycollate sodium starch
IL141439A IL141439A (en) 1998-09-03 2001-02-15 An immediate-release tablet
IS5869A IS5869A (is) 1998-09-03 2001-02-28 Hraðlosandi tafla
ZA200101762A ZA200101762B (en) 1998-09-03 2001-03-01 Immediate release tablet.
NO20011085A NO20011085L (no) 1998-09-03 2001-03-02 Tablett med umiddelbar frigivningsvirkning
US10/347,968 US6875446B2 (en) 1998-09-03 2003-01-21 Method for prophylaxis and/or treatment of thromboembolism
RU2005100986/15A RU2005100986A (ru) 1998-09-03 2005-01-19 Таблетка с немедленным высвобождением
US11/095,933 US20050208128A1 (en) 1998-09-03 2005-03-31 Immediate release tablet
JP2006309957A JP2007039472A (ja) 1998-09-03 2006-11-16 速放性錠剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802973A SE9802973D0 (sv) 1998-09-03 1998-09-03 Immediate release tablet

Publications (1)

Publication Number Publication Date
SE9802973D0 true SE9802973D0 (sv) 1998-09-03

Family

ID=20412467

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802973A SE9802973D0 (sv) 1998-09-03 1998-09-03 Immediate release tablet

Country Status (32)

Country Link
US (3) US6521253B1 (fr)
EP (2) EP1109537B1 (fr)
JP (2) JP4026678B2 (fr)
KR (2) KR20060097071A (fr)
CN (3) CN1544088A (fr)
AR (1) AR029313A1 (fr)
AT (1) ATE286385T1 (fr)
AU (1) AU746129B2 (fr)
BR (1) BR9913400A (fr)
CA (1) CA2341397C (fr)
CZ (1) CZ300830B6 (fr)
DE (1) DE69923074T2 (fr)
EE (1) EE200100134A (fr)
ES (1) ES2234296T3 (fr)
HU (1) HU227278B1 (fr)
ID (1) ID29629A (fr)
IL (2) IL141439A0 (fr)
IS (1) IS5869A (fr)
MY (1) MY124359A (fr)
NO (1) NO20011085L (fr)
NZ (2) NZ539749A (fr)
PL (1) PL195603B1 (fr)
PT (1) PT1109537E (fr)
RU (2) RU2252751C2 (fr)
SA (1) SA99200683B1 (fr)
SE (1) SE9802973D0 (fr)
SK (1) SK285507B6 (fr)
TR (2) TR200502188T2 (fr)
TW (1) TW561056B (fr)
UA (1) UA75567C2 (fr)
WO (1) WO2000013671A1 (fr)
ZA (1) ZA200101762B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
HUP0301390A3 (en) * 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CN1642546A (zh) * 2002-03-28 2005-07-20 帝人株式会社 含有单一晶型的固体制剂
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
CA2552114A1 (fr) * 2003-12-31 2005-07-21 Actavis Group Hf Formulations solides d'administration de galantamine
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
JP5344289B2 (ja) * 2006-06-29 2013-11-20 株式会社ツムラ 漢方エキス含有錠剤組成物
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102008014237A1 (de) * 2008-03-14 2009-09-17 J. Rettenmaier & Söhne Gmbh + Co. Kg Direktverpressbares Tablettierhilfsmittel
JP5583659B2 (ja) * 2009-03-13 2014-09-03 富山化学工業株式会社 ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミド含有錠剤および造粒末
CA3146333A1 (fr) 2009-03-18 2010-09-23 Resverlogix Corp. Derives de la phenyl-quinazolin-4(3h)-one et de la phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one et leurs compositions utiles comme agents anti-inflammatoires
LT2421533T (lt) 2009-04-22 2018-12-27 Resverlogix Corp. Nauji priešuždegiminiai agentai
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
WO2016147053A1 (fr) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601833A (en) 1978-02-06 1981-11-04 Wellcome Found Antacid formulation
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US5430023A (en) * 1990-09-28 1995-07-04 Eli Lilly And Company Tripeptide antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5532267A (en) * 1992-02-10 1996-07-02 Torii & Co., Ltd. Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5436229A (en) * 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
MX9700152A (es) 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
EP0803251B1 (fr) 1996-04-23 2002-07-17 Janssen Pharmaceutica N.V. Formes solides d'administration de cisapride à libération immédiate et indépendente du PH
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
JP2001500875A (ja) * 1996-09-18 2001-01-23 メルク エンド カンパニー インコーポレーテッド 心臓血管系疾患関連の危険性を減らす併用治療法
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
CA2239931A1 (fr) 1998-07-15 2000-01-15 Bernard Charles Sherman Comprime pharmaceutique comprenant de la norfloxacine
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
JP2002541092A (ja) 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
AT4327U1 (de) 1999-04-13 2001-06-25 Beecham Pharm Pte Ltd Pharmazeutische formulierung

Also Published As

Publication number Publication date
DE69923074T2 (de) 2005-12-08
CN1158070C (zh) 2004-07-21
AU746129B2 (en) 2002-04-18
NZ539749A (en) 2006-11-30
KR100696350B1 (ko) 2007-03-20
IL141439A0 (en) 2002-03-10
RU2005100986A (ru) 2006-06-20
NZ509943A (en) 2004-01-30
ZA200101762B (en) 2002-06-03
PL195603B1 (pl) 2007-10-31
JP2002524412A (ja) 2002-08-06
TR200502188T2 (tr) 2006-12-21
AU5892499A (en) 2000-03-27
SA99200683B1 (ar) 2006-12-05
US6521253B1 (en) 2003-02-18
US20030118644A1 (en) 2003-06-26
TR200100666T2 (tr) 2001-08-21
EP1527787A1 (fr) 2005-05-04
KR20060097071A (ko) 2006-09-13
ES2234296T3 (es) 2005-06-16
DE69923074D1 (de) 2005-02-10
US20050208128A1 (en) 2005-09-22
IL141439A (en) 2006-07-05
RU2252751C2 (ru) 2005-05-27
WO2000013671A1 (fr) 2000-03-16
CN1315855A (zh) 2001-10-03
UA75567C2 (en) 2006-05-15
KR20010090436A (ko) 2001-10-18
BR9913400A (pt) 2001-05-22
ID29629A (id) 2001-09-06
ATE286385T1 (de) 2005-01-15
JP2007039472A (ja) 2007-02-15
CZ2001774A3 (cs) 2001-10-17
CA2341397A1 (fr) 2000-03-16
AR029313A1 (es) 2003-06-25
PT1109537E (pt) 2005-04-29
CN1544088A (zh) 2004-11-10
NO20011085D0 (no) 2001-03-02
HUP0103886A2 (hu) 2002-04-29
CZ300830B6 (cs) 2009-08-19
CN1951371A (zh) 2007-04-25
EP1109537B1 (fr) 2005-01-05
IS5869A (is) 2001-02-28
PL346545A1 (en) 2002-02-11
JP4026678B2 (ja) 2007-12-26
TW561056B (en) 2003-11-11
MY124359A (en) 2006-06-30
US6875446B2 (en) 2005-04-05
SK2812001A3 (en) 2001-09-11
NO20011085L (no) 2001-05-03
EE200100134A (et) 2002-06-17
HU227278B1 (en) 2011-01-28
SK285507B6 (sk) 2007-03-01
HUP0103886A3 (en) 2002-08-28
EP1109537A1 (fr) 2001-06-27
CA2341397C (fr) 2009-02-03

Similar Documents

Publication Publication Date Title
SE9802973D0 (sv) Immediate release tablet
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
GC0000046A (en) Compositions for use in well construction, repair and/or abandonment.
TR200707263T2 (tr) Uzun sürede dışarıya yayılan eritromisin türevi formülleri.
BG104779A (en) Inhibitors of phospholipase enzymes
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
EP0960621A3 (fr) Compositions pharmaceutiques comprenant du sildenafil
HUP0104987A3 (en) Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
HK1052191A1 (en) Glycopeptide phosphonate derivatives
ES2157881T3 (es) Metanosulfonato de paroxetina.
HRP20010277B1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
AU5472101A (en) Polymer composition for pipes
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
NO20012727L (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
MXPA03008896A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos.
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
MXPA03000624A (es) Composiciones y peliculas para la elaboracion de capsulas.
AU2001252225A1 (en) Oral composition comprising chlorhexinine and maltitol or erythritol or a mixture thereof
PT1259261E (pt) Composicoes farmaceuticas que compreendem terbinafina
AR021249A1 (es) COMPOSICIoN DE CONFITURA BLANDA NO PEGAJOSA.
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
BG106031A (en) Prucalopride oral solution
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy